Prime Medicine
PRMEPrime Medicine is a biotechnology company pioneering Prime Editing, a next-generation gene editing technology designed to precisely rewrite DNA sequences without causing double-stranded breaks.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Segments
By segment
Competitors
By market cap
By revenue growth
Profile
Prime Medicine is a biotechnology company pioneering Prime Editing, a next-generation gene editing technology designed to precisely rewrite DNA sequences without causing double-stranded breaks. The company develops curative genetic medicines for diseases driven by genetic alterations, focusing on liver-directed in vivo therapies and ex vivo cell engineering. Their modular platform is engineered to accelerate drug development by utilizing shared delivery systems and editor components across multiple therapeutic indications.
Prime Medicine is a leader in the emerging field of Prime Editing, positioning itself as a more precise and versatile alternative to first-generation CRISPR nucleases and base editors.
Questions, answered.
- What is Prime Medicine's market cap?
- Prime Medicine (PRME) has a market capitalization of $543.7M and trades on NASDAQ.
- Who are Prime Medicine's competitors?
- Prime Medicine's key competitors include Intellia Therapeutics, Editas Medicine, CRISPR Therapeutics, and others. These companies compete in similar markets and product categories.
- Who does Prime Medicine partner with?
- Prime Medicine's notable partners include Bristol-Myers Squibb, Beam Therapeutics, Broad Institute, and others.
- Where is Prime Medicine headquartered?
- Prime Medicine is headquartered in United States of America and employs approximately 234 people. It has been publicly traded since 2022.